Adenocarcinoma of prostate
Item
1. histologically confirmed adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
First line treatment Prostate carcinoma | Radical prostatectomy | External Beam Radiation Therapy | Brachytherapy
Item
2. prior primary therapy for prostate cancer, including radical prostatectomy, external beam radiation therapy, or brachytherapy.
boolean
C1708063 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0194810 (UMLS CUI [2])
C1517033 (UMLS CUI [3])
C0006098 (UMLS CUI [4])
PSA measurement | Antiandrogen therapy | PSA Nadir | PSA measurement Following Quantity
Item
3. serum psa > 0.2 ng/dl following 8 months of androgen deprivation therapy or a nadir psa >0.2 ng/dl and at least 1 subsequent psa values at the same or higher level, if prior to 8 months.
boolean
C0201544 (UMLS CUI [1])
C0279492 (UMLS CUI [2])
C0138741 (UMLS CUI [3,1])
C1708760 (UMLS CUI [3,2])
C0201544 (UMLS CUI [4,1])
C0332282 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
Serum testosterone measurement
Item
4. serum testosterone < 50 ng/ml.
boolean
C0428413 (UMLS CUI [1])
Neoplasm Metastasis Absent Bone scan
Item
5. no evidence of metastases on bone scan.
boolean
C0027627 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0203668 (UMLS CUI [1,3])
Neoplasm Metastasis Absent CT of abdomen | Neoplasm Metastasis Absent CT of Pelvis
Item
6. no evidence of metastases on ct scan of the abdomen and pelvis.
boolean
C0027627 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0412620 (UMLS CUI [1,3])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0412628 (UMLS CUI [2,3])
ECOG performance status
Item
7. ecog performance status < 2.
boolean
C1520224 (UMLS CUI [1])
Laboratory criteria | Absolute neutrophil count | Platelet Count measurement
Item
8. laboratory criteria for entry: absolute neutrophil count ≥ 1.2 k/cu mm, platelets ≥
boolean
C0022877 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Creatinine measurement, serum
Item
100 k/cu mm, serum bilirubin ≤ upper limit of normal (uln), sgot and sgpt ≤ 1.5 times institutional uln if alkaline phosphatase ≤ uln, alkaline phosphatase ≤ 5 times uln if sgot and sgpt are ≤ uln, a serum creatinine ≤ 2 times institutional uln.
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
Informed Consent
Item
9. signed informed consent.
boolean
C0021430 (UMLS CUI [1])
Neoplasms, Second Primary | Exception Skin carcinoma Treated
Item
1. a second active malignancy during the last 5 years, except adequately treated non-melanoma skin cancer.
boolean
C0085183 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
Life Expectancy
Item
2. life expectancy < 3 months.
boolean
C0023671 (UMLS CUI [1])
Peripheral Neuropathy CTCAE Grades
Item
3. grade 2 or higher peripheral neuropathy.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Investigational New Drugs
Item
4. prior investigational agent within the past 28 days.
boolean
C0013230 (UMLS CUI [1])
Antiandrogen therapy Initial | PSA decreased Percentage | Raised PSA
Item
5. less than a 10% decrease (or continued rise) in psa in response to initial androgen-deprivation therapy.
boolean
C0279492 (UMLS CUI [1,1])
C0205265 (UMLS CUI [1,2])
C0178414 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0178415 (UMLS CUI [3])
Duration Since Antiandrogen therapy Initiation
Item
6. more than 12 months since initiation of androgen-deprivation therapy.
boolean
C0449238 (UMLS CUI [1,1])
C1711239 (UMLS CUI [1,2])
C0279492 (UMLS CUI [1,3])
C1704686 (UMLS CUI [1,4])
docetaxel
Item
7. prior docetaxel chemotherapy.
boolean
C0246415 (UMLS CUI [1])
Adrenal Cortex Hormones Started | Exception inhaled steroids | Exception topical steroids | CORTICOSTEROIDS FOR SYSTEMIC USE Dose Stable eligible
Item
8. patients recently (within 28 days) started on corticosteroids, with the exception of inhaled and topical steroids. patients on stable doses of systemic corticosteroids will be eligible.
boolean
C0001617 (UMLS CUI [1,1])
C1272689 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C2065041 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C2064827 (UMLS CUI [3,2])
C3653708 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
C1548635 (UMLS CUI [4,4])